Cochrane · systematic review · CD006847
Gefitinib for advanced non‐small cell lung cancer
Sim, EHA, Yang, IA, Wood‐Baker, R, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 45.5%High 6 · 54.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Gefitinib compared to chemotherapy for first‐line treatment of advanced NSCLC
Population: advanced NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Gefitinib vs chemotherapy | HR 0.98 [0.91, 1.46] | 2 studies · 275 participants | Moderate Downgraded: imprecision, indirectness |
Progression‐free survival (PFS) Gefitinib vs chemotherapy | HR 1.19 [0.86, 1.65] | 2 studies · 275 participants | Moderate Downgraded: imprecision, indirectness |
Gefitinib compared to chemotherapy for second‐line treatment of advanced NSCLC
Population: advanced NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Gefitinib vs chemotherapy | HR 1.02 [0.91, 1.15] | 2 studies · 1607 participants | Moderate Downgraded: imprecision |
Progression‐free survival (PFS) Gefitinib vs chemotherapy | HR 1.04 [0.92, 1.17] | 2 studies · 1607 participants | Moderate Downgraded: imprecision |
Gefitinib compared to chemotherapy for advanced NSCLC ‐ toxicity
Population: advanced NSCLC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Skin rash Gefitinib vs chemotherapy | RR 2.4 [1.08, 5.31] | 4 studies · 1858 participants | High |
Constipation Gefitinib vs chemotherapy | RR 0.41 [0.17, 0.97] | 3 studies · 1719 participants | High |
Fatigue Gefitinib vs chemotherapy | RR 0.16 [0.03, 0.88] | 2 studies · 275 participants | Moderate Downgraded: imprecision, indirectness |
Asthenia Gefitinib vs chemotherapy | RR 0.51 [0.35, 0.75] | 3 studies · 1773 participants | High |
Neurotoxicity Gefitinib vs chemotherapy | RR 0.07 [0.01, 0.34] | 2 studies · 1529 participants | High |
Neutropenia Gefitinib vs chemotherapy | RR 0.04 [0.02, 0.06] | 4 studies · 1857 participants | High |
Febrile neutropenia Gefitinib vs chemotherapy | RR 0.12 [0.06, 0.23] | 3 studies · 1768 participants | High |